| Value | ₹484.5 Cr |
|---|
NSE filing, NSE: ABCAPITAL. Summary written from the filing by ALFA Finder's alert engine.
Aditya Birla Capital Ltd: key numbers
- Share price
- ₹379.95
- Market cap
- ₹1,04,031 Cr
- Revenue (annual)
- ₹45,509 Cr
- Net profit (annual)
- ₹3,764 Cr
- P/E (TTM)
- 22.9×Sector 22.3×
- Promoter holding
- 68.82%+0.01% QoQ
- FII holding
- 8.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aditya Birla Capital Ltd
All →Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 148,098 equity shares on November 4, 2026, under its ESOP and RSU/PSU schemes. Paid-up capital rises to ₹27,38,15,47,350 after the allotment.
Aditya Birla Capital Debt & Borrowing
Aditya Birla Capital confirms full utilization of NCD and sub-debt issue proceeds for Q3 FY27 under Reg 52(7). No deviation from intended use was reported across 12 listed tranches.
Aditya Birla Capital Other Announcement
Aditya Birla Capital filed a quarterly Monitoring Agency Report confirming no deviation in utilizing its ₹4,000 Crore Preferential Issue proceeds. The filing covers the quarter ended 30 September 2026.
Aditya Birla Capital Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹16,545 Cr (+31% y-o-y) and PAT ₹1,288 Cr (+38% y-o-y). Lending portfolio ₹2,33,930 Cr (+32%). Strategy centres on AI-led underwriting and omnichannel distribution.
Aditya Birla Capital Q2 FY27 Results: Net Profit ₹1,353 Cr, Up 40.9% YoY
Aditya Birla Capital Ltd reported revenue from operations of ₹14,003 Cr (+32.2% YoY) and net profit of ₹1,353 Cr (+40.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,353 Cr · +40.9% YoY
Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 24,884 equity shares under its ESOP/RSU/PSU schemes on October 23, 2026. Paid-up capital increased to 27,38,00,66,370 shares of ₹10 each.
Other merger & restructuring announcements
All →Narayana Hrudayalaya Merger & Restructuring
Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.
Abans Enterprises Merger & Restructuring
Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.
- Execution
- Expected within one year, subject to approvals and statutory formalities
Max Estates Merger & Restructuring Worth ₹0.01 Cr
Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.
- Value
- ₹0.01 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr